693 matches
-
626-632. 4. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective multicentric randomized phase III study of imatinib în patients with advanced gastrointestinal stromal tumours comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113. 5. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib în patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103. 6. DeMatteo RP, Gold JS, Saran
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Owzar KR, Maki R et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) în patients with completely resected localized primary gastrointestinal stromal tumour (GIST): North American intergroup phase III trial ACOSOG Z9001. ASCO Annual Meetings Proceedings Part I. J Clin Oncol 2007; 25 (18 Suppl): 10079. 8. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib în patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368: 1329-1338
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
outcomes of laparoscopic resection of gastric gastrointestinal stromal tumours. Ann Surg 2006; 243: 738-745. 14. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumours after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-2331. 15. Van Glabbeke M, Verveij J, Casali PG et al. Initial and late resistance to imatinib în advanced gastrointestinal stromal tumours are predicted by different prognostic factors: a European Organizațion for Research and Treatment of Cancer
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
J, Casali PG et al. Initial and late resistance to imatinib în advanced gastrointestinal stromal tumours are predicted by different prognostic factors: a European Organizațion for Research and Treatment of Cancer - Italian Sarcoma Group - Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23: 5795-5804. 16. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival în gastrointestinal stromal tumours with high-dose imatininb: randomized trial. Lancet 2004; 364: 1127-1134. 17. Zalcberg JR, Verveij J, Casali PG et al. Outcome of patients
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Med J 1995; 311: 899909. 5. Depierre A, Milleron B, Moro-Sibilot D et al. French Thoracic Cooperative Group. Preoperative chemotherapy followed by surgery compared with primary surgery în resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20: 247-253. 6. The International Adjuvant Lung Cancer Trial Collaborative Group Cisplatin-based adjuvant chemotherapy în patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360. 7. Winton T, Livingston R, Johnson D et al
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
individual patient data meta-analysis. Lung Cancer 2005; 47: 81-83. 10. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care în patients with non-small cell lung cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000; 18: 2095-2103. 11. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel în patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597. 12. Shepherd FA
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
cancer previously treated with platinumbased chemotherapy. J Clin Oncol 2000; 18: 2095-2103. 11. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel în patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-1597. 12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Național Cancer Institute of Canada Clinical Trials Group. Erlotinib în previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123-132. 13. Auperin A, Le
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
1764 patients. Ann Oncol 2006; 17: 473483. 14. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy în combination with mitomycin, vindesine, and cisplatin în unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692-2699. 15. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for nonsmallcell lung cancer. N Engl J Med 2006; 355: 2542-2550. 16. Reck M, von Paul J, Zatloukal P et al. Phase
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
cancer. N Engl J Med 2006; 355: 2542-2550. 16. Reck M, von Paul J, Zatloukal P et al. Phase III study of cisplatin plus gemcitabine with either placebo or bevacizumab as firstline therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol 2009; 27: 1227-1234. 17. Pirker R, Pereira JR, Szczesna A et al. Cetuximab plus chemotherapy în patients with nonsmallcell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009; 373: 15251531. Cancerul pulmonar microcelular Recomandările ESMO pentru diagnosticare
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
3: 1067-1077. 2. Sundstrom S, Bremnes RM, Kaasas S et al. Cisplatin and etoposide regimen is superior to cyclophosphanide, epirubicin, and vincristine regimen în small cell lung cancer: results form a randomized phase III trial with 5 years' follow-up.J Clin Oncol 2002; 20: 4665-4672. 3. Pujol JL, Carestia L, Daures JP. Is there a case for cisplatin în the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin containing regimen versus a regimen without this alkylating
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Med 1992; 327: 1618-1624. 6. Spiro SG, James LE, Rudd RM et al. Early compared with late radiotherapy în combined modality treatment for limited disease small-cell lung cancer: A London Lung Cancer Group Multicenter Randomized Clinical Trials and Metaanalysis. J Clin Oncol 2006; 24: 3823-3830. 7. De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival în limited-disease small-cell lung cancer
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
2006; 24: 3823-3830. 7. De Ruysscher D, Pijls-Johannesma M, Bentzen SM et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival în limited-disease small-cell lung cancer. J Clin Oncol 2006; 24: 1057-1063. 8. Pijls-Johannesma MC, De Ruysscher D, Lambin P et al. Early versus late chest radiotherapy for limited stage small cell lung cancer. Cochrane Database Syst Rev 2005; 1: CD004700. 9. Fried DB, Morris DE, Poole C
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
stage small cell lung cancer. Cochrane Database Syst Rev 2005; 1: CD004700. 9. Fried DB, Morris DE, Poole C et al. Systematic review evaluating the timing of thoracic radiation therapy în combined modality therapy for limited-stage smallcell lung cancer. J Clin Oncol 2004; 22: 4837-4845. 10. Auperin A, Arriagada R, Pignon JP et al. Prophylactic cranial irradiation for patients with smallcell lung cancer în complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999; 341: 476-484. 11. Slotman
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
phase III study. Semin Oncol 1994; 21 (suppl 6): 23-30. 14. O'Brien ME, Ciuleanu TE, Tsekov H et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan în patients with relapsed small-cell lung cancer. J Clin Oncol 2006; 24: 5441-5447. Mezoteliomul pleural malign Recomandările ESMO pentru diagnosticare, tratament și monitorizare R. Stahel*1), W. Wedre*2) amp; E. Felip*3) *1) Clinic and Policlinic of Oncology; *2) Department of Thoracic Surgery, University Hospital of Zⁿ'62rich
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
options and new advances în malignant mesothelioma. Ann Oncol 2005; 16: 345-351. 11. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed în combination with cisplatin versus cisplatin alone în patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644. 12. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed în patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Randomized phase III study of cisplatin with or without raltitrexed în patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the Național Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889. 13. Bottomley A, Gaafar R, Manegold C et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed în patients with malignant pleural mesothelioma
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed în patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and Național Cancer Institute, Canada. Intergroup Study. J Clin Oncol 2006; 24: 1435-1442. 14. Jassem J, Ramlau R, Santoro A et al. A randomised phase III trial comparing pemetrexed plus best supportive care vs best supportive care în previously treated patients with advanced malignant mesothelioma. Ann Oncol 2006; 17
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
în the management of invasive bladder cancer by radical cystectomy. Eur Urol 1998; 33(Suppl):25-26. 5. Stien JP, Lieskovsky G, Cote R, et al. Radical cystectomy în the treatment of invasive bladder cancer: long-term results în 1054 patients. J Clin Oncol 2001; 19:666-675. 6. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19:89-93. 7. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined modality treatment and selective organ preservation în invasive bladder
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Stien JP, Lieskovsky G, Cote R, et al. Radical cystectomy în the treatment of invasive bladder cancer: long-term results în 1054 patients. J Clin Oncol 2001; 19:666-675. 6. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19:89-93. 7. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined modality treatment and selective organ preservation în invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061-3071. 8. Shipley WU, Kaufman DS, Zehr EM, et
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
6. Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 2001; 19:89-93. 7. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined modality treatment and selective organ preservation în invasive bladder cancer: long-term results. J Clin Oncol 2002; 20:3061-3071. 8. Shipley WU, Kaufman DS, Zehr EM, et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60:62-67. 9. Hussain SA, Stocken DD, Peake
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Oncol Hematol (2003) 47:195-206. 18. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, cisplatin vinblastine, doxorubicin în advanced or metastatic bladder cancer: results of a large randomized, multinational, phase III study. J Clin Oncol 2000; 17:3068-3077. 19. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin în patients with bladder cancer. J Clin Oncol
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
J Clin Oncol 2000; 17:3068-3077. 19. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin în patients with bladder cancer. J Clin Oncol 2005; 23:4602-4608. 20. Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology 2007; 69 (1 Suppl):62-79. 21. Bellmunt J, von der
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Maase H, Mead GM, et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) în patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy. EORTC 30987/Intergroup Study. În: J Clin Oncol. 2007; ASCO Annual Meeting Proceedings part I, vol. 25, no. 18S. 22. Bellmunt J, Maroto P, Mellado B, et al. Phase II study of sunitinib as first line treatment în patients with advanced urothelial cancer ineligibile for cisplatin-based chemotherapy
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
Maase H, Theodore C, et al. Randomized phase III trial of vinflunine (VFL) plus best supportive care (BSC) versus BSC alone as 2nd line therapy after a platinum-containing regimen, în advanced transitional cell carcinoma of the urothelium (TCCU). În: J Clin Oncol. 2008; ASCO Annual Meeting Proceedings part I, vol. 26. Carcinomul renal: Recomandările ESMO pentru diagnosticare, tratament și monitorizare B. Escudier*1) amp; V. Kataja*2) *1) Institut Gustave Roussy, Villejuif, France; *2) Department of Oncology, Vaasa Central Hospital, Vaasa
EUR-Lex () [Corola-website/Law/227406_a_228735]
-
al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. 7. Motzer RJ, Bacik J, Schwartz LH et al. Prognostic factors for survival în previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-463. 8. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin 2 therapy. J Clin Oncol 1995; 13: 688-696. 9. Escudier B
EUR-Lex () [Corola-website/Law/227406_a_228735]